Extended-Release Buprenorphine
Extended-Release Buprenorphine
Overview
Extended-release buprenorphine refers to long-acting pharmaceutical formulations of buprenorphine—a partial mu-opioid receptor agonist—designed to deliver sustained therapeutic plasma concentrations over weeks to months from a single administration. Unlike daily sublingual buprenorphine-naloxone (Suboxone), these formulations eliminate the need for daily dosing and the associated risks of diversion, missed doses, and precipitated withdrawal. The primary approved indication is the treatment of moderate-to-severe opioid use disorder (OUD). Two principal delivery platforms have reached clinical use: subcutaneous injectable depots, most notably Sublocade (a PLGA-based in situ forming implant utilizing the Atrigel technology system), and long-acting injectable buprenorphine (LAIB) products such as Brixelle/Buvidal, which employ small-volume injectable depots administered weekly or monthly. By maintaining stable buprenorphine serum levels, extended-release formulations reduce cravings, suppress illicit opioid use, and minimize the peaks and troughs in plasma concentration that can complicate adherence with short-acting alternatives.
The pharmacological rationale centers on buprenorphine's high mu-opioid receptor affinity and slow receptor dissociation kinetics, which together produce durable opioid blockade and attenuation of withdrawal even at trough plasma levels achievable with monthly dosing. As a partial agonist with a ceiling effect on respiratory depression, buprenorphine retains a favorable safety profile relative to full agonists such as methadone, making extended-release delivery clinically viable without the cardiac monitoring burden associated with methadone. The shift toward injectable or implantable formulations represents a significant evolution in opioid substitution therapy (OST), addressing structural barriers to treatment retention that are particularly acute in rural, coastal, and underserved populations.
Focus of Latest Publications
Recent publications have examined extended-release buprenorphine from both clinical and formulation-development perspectives.
One study described a randomized controlled pilot trial of extended-release buprenorphine versus sublingual buprenorphine-naloxone in rural settings (RXR). The stated rationale was that the most recent formulation of injectable extended-release buprenorphine may improve treatment engagement and outcomes for people with OUD. This indicates ongoing interest in whether long-acting injectable delivery can address barriers common in rural care, such as access, retention, and medication adherence.
Several studies focused on long-acting injectable buprenorphine in real-world treatment settings. A retrospective cohort study from Cornwall, South West England, used treatment outcome profile data to examine outcomes among individuals receiving long-acting injectable buprenorphine in rural and coastal contexts. The publication framed long-acting injectable buprenorphine as a potential alternative to traditional treatments such as methadone, with possible benefits in adherence and outcomes. Another article, “The matter of mattering in depot buprenorphine treatment,” discussed long-acting injectable buprenorphine combined with social and health related interventions in a Danish clinic, highlighting the importance of treatment experience and service context in depot buprenorphine care.
Extended-release buprenorphine was also relevant to formulation science. A 2026 Journal of Controlled Release paper described the development of a compositionally equivalent buprenorphine in situ forming implant, identified as Sublocade, using a PLGA-based system designed for sustained delivery with monthly dosing for moderate to severe OUD. The study emphasized the product’s role as a sustained-release partial mu-opioid receptor agonist formulation. This work reflects continued optimization of depot delivery systems for buprenorphine.
In addition, the broader buprenorphine treatment landscape appeared in studies that are not exclusively about extended-release formulations but are relevant to its clinical context. A qualitative exploration from the HPTN 094 INTEGRA trial examined perceptions of buprenorphine-naloxone treatment and fear of precipitated withdrawal among participants and staff in a mobile unit delivering integrated MOUD and HIV services for people with OUD who inject drugs. Although this study centered on buprenorphine-naloxone rather than extended-release buprenorphine specifically, it is relevant because it addresses barriers to buprenorphine adoption in integrated care settings, including HIV infection-related service delivery.
Other publications addressed buprenorphine/naloxone in pain-related and palliative care contexts. A pragmatic Canadian multisite trial analyzed differential impacts of methadone and buprenorphine/naloxone on pain-related outcomes among people with non-heroin opioid use disorder, noting that both therapies have analgesic properties. A simulation-based curriculum for end-of-life crises and symptom management included initiation of buprenorphine-naloxone for cancer-associated pain in a patient with OUD. These studies reinforce the broader clinical relevance of buprenorphine-based therapies, including extended-release formulations, in settings where pain management and OUD treatment overlap.